Assessing new anticancer therapeutics in clinical trials is a vital step in evaluating the toxicity and efficacy of treatment before its approval for widespread use. Throughout these trials, many patients encounter a variety of side effects, ranging from physical ailments such as nausea or rash to psychological symptoms such as depression or anxiety. While it is standard practice to record clinician-reported outcomes to characterize safety, there is no current standard requirement for the use of patient-reported outcomes (PROs) in cancer clinical trials.Read More
Skin cancer is the most commonly diagnosed cancer in the United States. Every year, about 5 million Americans are treated for various forms of the disease.
Skin cancer types include basal and squamous cell cancers, as well as melanoma, the deadliest form of skin cancer. About 73,870 Americans are expected to be diagnosed with melanoma this year. Survival rates are significantly higher when the disease is diagnosed at its earliest stage.Read More
Multiple myeloma arises in immune cells called plasma cells. It is one of the most commonly diagnosed hematological malignancies in the United States, with more than 30,000 new cases expected in 2018.Read More
Norman E. “Ned” Sharpless, MD, who became director of the National Cancer Institute in October 2017, recently unveiled areas of opportunity that he believes are particularly important for accelerating cancer research.Read More
The concept of body mass index, or BMI, was introduced in the 19th century by the Belgian statistician Adolphe Quetelet. Quetelet sought to define “L’homme Moyen,” or the “Average Man,” …Read More
Cigarette smoking is linked to 18 different types of cancer. It is the leading preventable cause of cancer in the United States, accounting for 19 percent of the 1,570,978 cancers diagnosed in U.S. adults ages 30 and older in 2014, according to the latest research. Another 0.4 percent of the cancer diagnoses in the U.S. that year were attributable to exposure to secondhand smoke.
That’s why February, which is National Cancer Prevention Month, is a good time to raise awareness of the dangers of cigarette smoking and exposure to secondhand smoke.Read More
The American Association for Cancer Research (AACR) recently appointed Chi Van Dang, MD, PhD, as the new editor-in-chief of Cancer Research, arguably the most influential journal in cancer research today.Read More
Prostate cancer is one of the most common cancers diagnosed in the United States. About one-third of men diagnosed with prostate cancer have a tumor that grows very slowly, making it very unlikely that the disease will progress to become a clinical problem. Characterizing new ways to identify these cancers is an area of active research investigation.Read More
Several clinical trials are underway in which PARP inhibitors are being tested in breast cancers, mostly triple-negative breast cancers, because they often harbor BRCA mutations and DNA repair deficiencies. Emerging studies show that the benefit of PARP inhibitors could extend beyond breast cancers with germline BRCA mutations.Read More
In recent years, the U.S. Food and Drug Administration has approved immune checkpoint inhibitors, a class of immunotherapy, to treat 10 different types of cancer, in addition to solid tumors located anywhere in the body that have certain DNA damage and repair-related biomarkers. However, only a small percentage of patients respond to these treatments, and they can have significant side effects. Researchers are looking for biomarkers that can identify patients who are likely to respond to immune checkpoint inhibitors.Read More